A detailed history of Jane Street Group, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 568,654 shares of RVNC stock, worth $1.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
568,654
Previous 163,913 246.92%
Holding current value
$1.46 Million
Previous $421,000 247.03%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.57 - $2.57 $1.04 Million - $1.04 Million
404,741 Added 246.92%
568,654 $1.46 Million
Q2 2024

Aug 14, 2024

BUY
$2.34 - $4.73 $56,188 - $113,576
24,012 Added 17.16%
163,913 $421,000
Q1 2024

May 15, 2024

BUY
$4.65 - $9.31 $384,629 - $770,085
82,716 Added 144.65%
139,901 $688,000
Q4 2023

Feb 14, 2024

SELL
$5.81 - $11.2 $521,720 - $1.01 Million
-89,797 Reduced 61.09%
57,185 $502,000
Q3 2023

Nov 14, 2023

BUY
$11.47 - $25.07 $401,392 - $877,324
34,995 Added 31.25%
146,982 $1.69 Million
Q2 2023

Aug 14, 2023

SELL
$24.7 - $37.61 $4.02 Million - $6.12 Million
-162,812 Reduced 59.25%
111,987 $2.83 Million
Q1 2023

May 15, 2023

BUY
$18.36 - $35.27 $4.58 Million - $8.79 Million
249,255 Added 975.79%
274,799 $8.85 Million
Q4 2022

Feb 14, 2023

SELL
$18.32 - $30.66 $4.06 Million - $6.79 Million
-221,521 Reduced 89.66%
25,544 $471,000
Q3 2022

Nov 14, 2022

BUY
$14.33 - $28.47 $2.96 Million - $5.88 Million
206,702 Added 512.11%
247,065 $6.67 Million
Q2 2022

Aug 16, 2022

SELL
$11.52 - $20.4 $690,888 - $1.22 Million
-59,973 Reduced 59.77%
40,363 $558,000
Q1 2022

May 17, 2022

BUY
$12.36 - $20.31 $873,060 - $1.43 Million
70,636 Added 237.83%
100,336 $1.96 Million
Q4 2021

Feb 15, 2022

SELL
$12.46 - $27.87 $78,012 - $174,494
-6,261 Reduced 17.41%
29,700 $485,000
Q3 2021

Nov 16, 2021

SELL
$25.78 - $33.21 $23,047 - $29,689
-894 Reduced 2.43%
35,961 $1 Million
Q4 2020

Feb 17, 2021

BUY
$23.41 - $28.34 $300,186 - $363,403
12,823 Added 53.36%
36,855 $1.05 Million
Q3 2020

Nov 17, 2020

BUY
$23.23 - $34.3 $558,263 - $824,297
24,032 New
24,032 $605,000
Q2 2019

Aug 15, 2019

SELL
$10.67 - $15.49 $213,709 - $310,249
-20,029 Closed
0 $0
Q1 2019

May 16, 2019

BUY
$15.4 - $20.39 $99,191 - $131,331
6,441 Added 47.4%
20,029 $316,000
Q4 2018

Feb 15, 2019

BUY
$18.06 - $24.96 $245,399 - $339,156
13,588 New
13,588 $274,000
Q1 2018

May 15, 2018

SELL
$29.15 - $37.4 $558,863 - $717,032
-19,172 Closed
0 $0
Q4 2017

Feb 15, 2018

BUY
$24.55 - $36.3 $470,672 - $695,943
19,172
19,172 $685,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.